Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3653841 A
Publication typeGrant
Publication dateApr 4, 1972
Filing dateDec 19, 1969
Priority dateDec 19, 1969
Publication numberUS 3653841 A, US 3653841A, US-A-3653841, US3653841 A, US3653841A
InventorsKlein Bernard
Original AssigneeHoffmann La Roche
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Methods and compositions for determining glucose in blood
US 3653841 A
Abstract
Colorimetric methods and compositions for quantitatively determining the glucose content of blood plasma or serum by heating a deproteinized sample of blood plasma or serum with an alkaline ferricyanide solution, followed by the addition of ferric ions and a 5-(2-pyridyl)-2H-1,4-benzodiazepine or water soluble salts thereof to produce a brilliant purple colored solution which can be quantitated by standard colorimetric means.
Images(2)
Previous page
Next page
Description  (OCR text may contain errors)

United States Patent Klein [451 Apr. 4, 1972 [54] METHODS AND COMPOSITIONS FOR DETERMINING GLUCOSEIN BLOOD OTHER PUBLICATIONS Hawk et a1., Practical Physiological Chemistry, 13th ed., Me-

[72] Inventor: Bernard Klein, New Hyde Park, NY. Hill QP514H4, 95 P- 567, 575 Assignee Hoffman La Roche I Nu N J Aloe Scientific Co., Catalog 103, p. 1011, 1041, 1065, 1073 I nc., ey,

22 Filed; 19, 19 9 Primary Examiner-Morris O. Wolk Assistant Examiner-R. M. Reese [21] APPI'NO: 8 At'torneySamuel L. Welt, Jon S. Saxe, Bernard S. Leon,

Gerald S. Rosen and R. Hain Swope [52] US. Cl. ..23/230 R, 23/230 B, 252/408,

260/239.3'D ABSTRACT [3;] int. ..C09k 3/2273?! Colorimetric methods and compositions for quantitatively 1 e o m 2SZ'I4O8 determining the glucose content of blood plasma or serum-by heating a deproteinized sample of blood plasma or serum with [56] R f cted an alkaline ferricyanide solution, followed by the addition'of e erences l ferric ions and a 5(2-pyridyl)-2H-l,4-benzodiazepine or UNITED STATES PATENTS water soluble salts thereof to produce a brilliant purple colored solution which can be quantitated by standard 3,098,717 7/1963 Ferrari, Jr ..23/230 colorimetric means 3,449,081 6/1969 Hughes ..23/253 3,506,404 4/1970 Evans et a1. ..23/230 B 11 Claims, 3 Drawing Figures SAMPLE O PLATE O0 O0 SAMPLE ml/min F WM 0,0I5 0.|o

DIALYZER DMC 19.9,;- 0 i N, SALINE 0.100 3140 MIXERS I i -l-@-f- AIR 0065 1.60 G; Fe (CN)? 0.!00 3.40

n AIR 0065 L60 A HEATING I U FeCl 0.073 200 BATH H2 I Q REAGENT 0.0m 2450 l I 3W6 wAsTE F/C 0.065 1.60 Cg PROPORTIOI'VING I 'Q TUBE SIZE INCHES RECORDER 5B0nm AUTOMATED GLUCOSE ANALYSIS FLOW DIAGRAM Patented April 4, 1972 2 Sheets-Sheet 2 SBOnm M FIG. 2

1 I I v 0 50 I00 200 300 40 mg GLUCOSE IOOml E C O (I) \0 1 I l 1 1 l 1 l 1' BACKGROUND OF THE INVENTION The need for a quantitatively accurate method for the deter- 5 B is selected from mination of glucose in blood, e.g. plasma and serum, using small amounts of specimen, yet which is simple enough to be effectively utilized in the clinical situation and sufficiently economical for mass screening has long been felt. In addition, it has been considered most desirable that such a method be readily adaptable to an automated sequential or continuous flow system in order that a great many samples may be processed rapidly and with the highest possible accuracy. There is a need forsuch an automated sequential or continuous flow of system which is capable of highly accurate results before the diagnostic testing of large numbers of persons for the incidence of diabetes among them. A simple accurate test, which is both rapid and reliable, is of great value as an aid in the detection and treatment of diabetes and as an adjunct to routine screening operations in clinics and for periodic screening of patients in hospitals, nursing homes and similar institutrons.

Many techniques have been developed for quantitatively determining the glucose content of blood, plasma or serum. One such technique utilizes the enzyme glucose oxidase which catalyzes the oxidation of glucose to gluconic acid. In the more common test, this enzyme is combined with a substance having a peroxidative activity which induces the oxidation of an indicator such as o-toluidine in the presence of hydrogen peroxide formed by the glucose oxidase. This method, though specific, has proved to be too complex, expensive and time consuming for general use.

Other further metric techniques which are adaptable to automated procedures have been found to be not sufficiently sensitive for todays standards or undesirable in that they require comparatively large volume of specimen.

The diagnostic compositions and methods of the present invention provide a reliable, convenient test for the quantitating of glucose in the blood as well as affording a method whereby the quantitative determination may be carried out in a continuous sequential or flow system. Further, the diagnostic compositions and methods of the present invention overcome many of the disadvantages of the prior art methods of determining glucose in blood by not requiring a high degree of laboratory skill and technology using a small specimen volume, yet being highly accurate in the clinical situation.

BRIEF SUMMARY OF THE INVENTION In accordance with the invention, a 5-(2-pyridyl)-2H-l,4- benzodiazepine or water soluble salt thereof preferably in combination with a buffer, is added with an aqueous solution of ferric chloride to deproteinized plasma or serum which has been treated with an aqueous alkaline ferricyanide solution, whereby a purple solution is obtained which can be quantitated as to its glucose content by standard colorimetric means.

DETAILED DESCRIPTION OF THE INVENTION In accordance with the invention a compound selected from the group consisting of compounds of the formula wherein A is selected from the group consisting of and and CH,; R is selected from the group consisting of halogen, hydrogen, trifluoromethyl, nitro and amino; R, is selected from the group consisting of H R1---Rg 9 hydrogen, lower alkyl and 1 Re C uHzn sisting of hydrogen, hydroxy, lower alkyl, lower alkoxy and lower alkanoyloxy; R is Z-pyridyl; R is selected from the group consisting of lower alkyl and hydrogen; R is selected and R and R where taken together with their attached nitrogen atom form a radical selected from the group consisting of piperazinyl, lower alkyl substituted piperazinyl, pyrrolidinyl, lower alkyl substituted pyrrolidinyl, piperidinyl and lower alkyl substituted piperidinyl; R is lower alkyl; and R is selected from the group consisting of lower alkyl and hydrogen and water soluble salts thereof, preferably in combination with a buffer, is added with an aqueous solution of ferric chloride to deproteinized blood plasma or serum which has been treated with an aqueous alkaline ferricyanide solution, whereby a purple solution is obtained which can be quantitated by standard colorimetric means.

Examples of benzodiazepine compounds of formula I above which are particularly suitable as the color-forming reagent in the process of this invention include the following:

7-bromo-l ,3-dihydro-l-[4-(4-methyl-l-piperazinyl)butyl]- 5-(2-pyridal)-2H-l ,4-benzodiazepin-2-one;

7-aminol ,3-dihydro-5-( 2-pyridyl)-2H-l ,4-benzodiazepin- 2-one;

benzodiazepin-2-one;

2H- 1 ,4-benzodiazepinel -yl)propyl]urea whose preparation is disclosed in US. Pat. No. 3,464,978 issued Sept. 2, 1969;

benzodiazepine;

7-amino-l ,3-dihydrol -methyl-5-( 2-pyridyl)- l H- l ,4-

benzodiazepine;

7-bromol ,3-dihydro-( 3-dimethylaminopropyl)-5-( 2- pyridyl)-2H- l ,4-benzodiazepin-2-one;

7-bromol ,3-dihydro-5-(2-pyridyl)-2I-I-l ,4-benzodiazepin- 2-one-4-oxide;

7-bromol ,3-dihydro-5-( 2-pyridyl)-2H- l ,4-benzodiazepin- 2-one;

7-bromol ,3-dihydrol B-hydroxypropyl)-2-( 2-pyridyl 2H- 1 ,4-benzodiazepin-2-one; and

7-bromo-5-( 2-pyridyl)-l ,3.-dihydrol 3-( N- cyanomethylamino )propyl]2I-I- 1 ,4-benzodiazepin-2-one whose preparation is disclosed in US. Pat. No. 3,464,978.

The term lower alkyl as used throughout this specification includes both straight and branched chain alkyl groups having from one to seven carbon atoms such as methyl, ethyl, propyl, isopropyl and the like. The term lower alkanoyloxy" refers to both straight chain and branched chain aliphatic carboxylic acid moieties such as acetoxy, propionyloxy, butyryloxy and the like. The term halogen includes bromine, chlorine, fluorine and iodine. Also included within-the purview of the present invention are the water soluble acid addition salts of the compounds of formula I above. Any conventional water soluble acid addition salts of the compounds of formula I above may be utilized in the process of this invention to quantitatively determine the iron content of aqueous solutions. Among the acid addition salts which can be utilized in accordance with this invention, includes salts of compounds of the formula I with organic or inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, acetic acid, formic acid, succinic acid, maleic acid, ptoluenesulfonic acid and the like.

The color differentiation with varying concentrations of ferrous ions produced by the compound of formula I above is such that the concentration of ferrous ions produced by the instant diagnostic reagent composition in situ can easily be determined by standard colorimetric instruments. Furthermore, the compounds of formula I are not sensitive to extraneous sources and therefore are not affected by trace contaminants. The method of this invention provides a simple colorimetric means for quantitatively determining the glucose content of blood plasma and serum.

In accordance with the present invention the glucose content of blood plasma or serum can be determined by first heating a deproteinized sample with an aqueous solution containing ferricyanide ions to form an aqueous solution containing gluconic acid and ferrocyanide ions, cooling the solution and adding an aqueous solution containing ferric ions and a compound of formula I above wherein ferricyanide and ferrous ions are formed and the ferrous ions thus produced react with the compound of formula I, preferably in the presence of a buffer, to produce a brilliant deep purple color and colorimetrically quantitating the amount of glucose present in the sample. This procedure provides a simple and quick method for quantitatively determining the glucose content of a blood sample which is ideally suited for routine diagnostic use.

In accordance with the present invention, the specimen to be tested is initially treated with a conventional neutral deproteinizing agent such as, for example, an aqueous solution of either sodium or barium hydroxide and zinc sulfate, or an acidic deproteinizing agent such as, for example, tungstic acid or trichloroacetic' acid. Of these, tungstic acid or an aqueous solution of barium hydroxide and zinc sulfate are preferred. The specimen is well mixed with the deproteinizing agent and centrifuged at high speed to obtain a clear supemate. A 0.1 ml. aliquot of the superna'te is then heated to from 90 C. to about 100 C. preferably about 95 C. with 2.0 ml. of an aqueous alkaline solution containing ferricyanide ions. The mixture is rapidly cooled after about 5 minutes heating and treated with 2.0 ml. of an aqueous solution containing ferric ions such as, for example, ferric chloride, and 2.0 ml. of an aqueous solution of a compound of the formula I. The solutions are mixed and the absorbance of the violet blue color which develops over about 10 minutes is measured at 580 nm against both a standard glucose solution similarly treated and a reagent blank.

The solution containing ferricyanide ions can be made from any water soluble ferricyanide salt which does not otherwise interfere with the reaction such as, for example, potassium ferricyanide and sodium ferricyanide. Potassium ferricyanide is preferred in the practice of the present invention. This reagent may be made in quantity if so desired and used as needed. The

appropriate amount of potassium ferricyanide is dissolved in an aqueous alkaline medium'such as, for example, a 2 percent sodium carbonate solution. The quantity of ferricyanide salt utilized in preparing the reagent is variable. However, a sufficient quantity must be utilized to react with all the glucose in the specimen to furnish a positive indication of elevated glucose blood levels when the diagnostic method of the present invention is being utilized as a diagnostic or a mass screening tool.

Generally, it is preferred that for each ml. of blood plasma or serum tested, the reagent solution contain from about l.8 x 10" moles to about 7.0 X 10 moles of ferricyanide salt, preferably from about 3.5 X 10" moles to about 5.0 X 10" moles per ml. of plasma or serum utilized.

The quantity of ferric ions added to the sample ferricyanide ion mixture is again variable. However, it is preferred to utilize a quantity of ferric ion slightly in excess of the molar quantity of ferricyanide ions added to the sample. The utilization of such an excess insures that there will be sufficient ferric ions present to react with the ferrocyanide ions generated by the initial reaction between the ferricyanideions and the glucose in the sample. The ferric ions may be supplied as any water soluble ferric salt which does not interfere with the diagnostic determination such as, for example, ferric chloride, ferric nitrate, ferric sulfate and the like. Of these, ferric chloride is preferred.

The quantity of the compound of formula I which is added to the aqueous mixture is variable. In all instances, however, there must be a sufficient quantity of the compound of formula I present to react with all of the ferrous ions generated bythe reaction between the ferric ions and the ferrocyanide ions. This quantity is most conveniently determined by equating the quantity of the compound of formula I with that of the ferric ions to insure the stoichiometry of the chelation reaction.

It is preferred to maintain the test medium at a pH of about 4.0 to about 5 .0, preferably about 4.5. This can most easily be accomplished by adding suitable buffers to the ferric ion reagent and the reagent containing the compound of formula I. Buffering these reagents also makes them stable in aqueous solution when they are made up in quantity for large scale laboratory testing.

In general, any recognized buffer pair suitable for the maintenance of such a pH range as described above can be utilized.

Preferably, there can be utilized as a buffer pair a water soluble salt of acetic acid and acetic acid. Of the water soluble salts of acetic acid sodium acetate is preferred. However, ammonium acetate, potassium acetate or other water soluble salt of acetic acid can be used, if desired. Although the quantities of the buffer pair comprising a water soluble acetic acid salt and acetic acid are variable, the present invention contemplates the use of a sufficient quantity of the acidcomponent, e.g. acetic acid, to provide a final test sample having a pH in the range of from about 4.5 to about 5.5. By final test sample is meant a solution containing the ferricyanide ions, the ferric ions and the benzodiazepine color reagent. In general, there is contemplated the preparation of a solution of both the ferric ions and the benzodiazepine color former which contains per liter about 1.0 mole of a water soluble salt of acetic acid to about 1.0 to about 2.0 moles of acetic acid.

From the foregoing description it is evident that thecompositions of the present invention may be utilized or handled as prepared aqueous stock solutions, aqueous concentrates or in a dry powder form. In either the concentrate or the powder form, sufficient buffering agents are added to stabilize the compositions when the working dilutions are made and maintain the pH of the reaction mixture at between 4.5 and 5.5 preferably about 4.8.

In utilizing the compositions of the present invention, the addition of the compound of formula I to the test system immediately produces the desired purple coloration. The color deepens as the reaction proceeds to completion. The reaction mixture ceases to undergo anycolor changes discernible to the naked eye after it has been allowed to stand for a short time at room temperature. Accordingly, in order to insure uniform coloring, the aqueous solution should be aliowed to stand until its color appears to have become constant. In general, it has been found that the full development of the purple color will occur over a period of from about 5 to minutes after the addition of the compound of formula I. In most cases 10 minutes is a sufficient period of time to allow for full color development.

The quantitation of the glucose in the colored sample can be carried out by any conventional colorimetric method utilizing standard spectrophotometers such as a Beckman Spectrophotometer, Coleman Spectrophotometer and the like.

The principle of the diagnostic method according to the present invention is based on a series of coupled reactions. Initially, glucose present in the sample undergoing analysis reduces the ferricyanide ion in the added first reagent to ferrocyanide ions, in turn form ferricyanide ions and ferrous ions with the addition of the second reagent which comprises a source of ferric ions such as, for example, ferric chloride, a buffer and a compound of the formula I. The ferrous ions thus generated react with the compound of the formula I to produce a brilliant deep purple color. The purple color is thereafter colorimetrically measured and the glucose content of the sample quantitatively determined.

The quantitative determination of the glucose content in a specimen is carried out as follows: the optical density of the purple color developed in the sample by the method of the present invention is measured against a reagent blank at 580 nm utilizing a standard spectrophotometer such as, for example, a Coleman Spectrophotometer, employing a cuvette with a 19 mm. light path. The quantity of glucose in the specimen is determined in the conventional manner from the absorbance of the specimen with reference to the absorbance of the color produced by a glucose standard similarly treated. The glucose content of the specimen is calculated in accordance with the following formula:

Glucose content of specimen (mg./ 100 ml.)

Absorbance of specimen Absorbance of standard As indicated heretofore, the present invention provides an extremely important diagnostic tool. In addition, the method of the present invention affords a rapid and accurate determination of the glucose content of body fluids such as plasma or serum with results that are characterized by a high degree of reproducibility.

In another aspect of the present invention, the analytical compositions as described are utilized in a method of analyzing the glucose content of body fluids automatically by discrete sequential sampling or by continuous flow apparatus. The latter method consists essentially of mixing specimens in continuous flow with normal saline, dialyzing the mixture to produce an aqueous protein-free solution containing the glucose, mixing the aqueous solution with an aqueous alkaline solution containing ferricyanide ions, passing the resulting mixture through a heating bath to raise the temperature thereof to about95 C., mixing the heated aqueous solution with an aqueous solution of a ferric salt and a compound of the formula I at a constant pH of from about 4.5 to about 5.5 and passing the resulting solution through an apparatus which quantitatively determines the glucose content thereof photometrically.

FIG. 1 is a schematic flow diagram illustrating a continuous flow automated system for analyzing glucose in biological fluids utilizing the diagnostic composition of the present invention.

FIG. 2 is a recording of the photometric response obtained when utilizing the automated system of FIG. 1.

FIG. 3 is a plot in terms of absorbance of the photometric response illustrated in FIG. 2.

In FIG. 1, a continuous flow automated testing system is,

showriglgrnati cally wherein a specimen sample to be tested, i.e. serum or plasma, is drawn up in sequence from separate sample cups in thesample plate which rotates at a constant speed to provide the system with 20-60 specimen samples with a 2:1 wash ratio per hour. A sample, so drawn, is mixed in flow with normal saline and passed through a glass mixing coil of conventional design. After the mixture has passed through the mixing coil, it is next pumped through a dialyzer module that is provided with a cellophane membrane or the like through which the glucose passes in aqueous solution by dialysis. The dialyzer module is maintained at a constant temperature of 37 C. The residual, non-diffusable portion of the sample is discarded. As the aqueous glucose solution passes through the dialyzer module membrane it is admixed with an aqueous alkaline solution containing ferricyanide ions, preferably in the form of potassium ferricyanide, the glucose and the ferricyanide ions are passed in solution through a heating bath which raises the temperature of the mixture to C. As this passage takes place the glucose and ferricyanide ions are reacting to form gluconic acid and ferrocyanide ions. The heated aqueous stream is then mixed in continuous flow with an aqueous solution containing ferric ions, preferably in the form of ferric chloride, and a reagent stream comprising the 5-(2-pyridyl)-2H-l ,4-benzodiazepine color reagent of formula I. The color reagent, preferably 7-bromo-l,3-dihydro-l- 3-dimethylaminopropyl)-5-( 2-pyridyl)-2I-I- l ,4- benzodiazepine-2-one is maintained at a pH of about 4.5 to 5.5, preferably at about 5.0. The mixture is then passed through a second mixing coil. As the mixture is in transit through this coil, the ferric ions and ferrocyanide ions react to form ferricyanide ions and ferrous ions which in turn react with the benzodiazepine color reagent to form a brilliant purple coloration. Photometric measurements are then performed at 580 nm in a 15 mm. flow-cell colorimeter, i.e., the absorbance of the solution to be tested is measured at 580 nm in a flow-cell colorimeter using a 580 nm filter. The results of the colorimetric readings are recorded on a conventionalrecording mechanism.

The continuous flow system illustrated in FIG. 1 aspirates at a rate of 20 to 60 specimens/hour. The rate of flow in ml./min. of the materials entering the system according to a preferred technique is illustrated in FIG. 1. The materials entering the system are pumped into it by any suitable pumping means adjusted to maintain the rate of flow illustrated in FIG. 1. The mechanism for the system of the present invention can be conveniently provided by a manifold assembly prepared in accordance with the system illustrated in FIG. 1 adaptable to the Technicon Autoanalyzer.

In FIG. 2 the absorbance of solutions containing graduated amounts of glucose, e.g. 50 mg./ ml., 100 mg./ 100 ml. etc. are plotted as a graph against concentration.

In FIG. 3 the photometric response of solutions containing different concentrations of glucose is demonstrated. The drawing illustrates four separate experiments, each of which represents passage through the automated system of FIG. 1 of a sequence of at least three solutions having glucose concentrations in the order of low to high to low, such as, for example, 50 mg. per 100 ml. to 400 mg. per 100 ml. to 50 mg. per 100 ml. These experiments were conducted to illustrate the sensitivity of the automated system. The difference in the response curve for similar concentration sequences represents a variance in the speed with which they were passed through the system.

The reagents utilized in connection with the automated procedure of glucose determination comprise aqueous solutions of a ferricyanide reagent, a ferric ion containing reagent and and the buffered color forming reagent. The ferricyanide reagent comprises sufficient ferricyanide to react with all the glucose in the sample, for example, 0.1 I5 g. potassium ferricyanide dissolved in 1 liter of 0.05 percent sodium hydroxide and 0.9 percent sodium chloride. The ferric ion containing solutions comprises suflicient ferric ions to react with all the ferrocyanide ions formed in the initial reaction, for example, 0. 2 7 g. ferric chloride dissolved in 1 liter of distilled water and buffered to a pH of about 4.5 with a sodium acetate/acetic acid buffer couple. The color-forming reagent comprises sufficient color-forming compound to react with the ferrous in the ions formed by the reaction of the ferric ions and the ferrocya nide ions, for'example, 2.0 g. of a compound of formula I, 82.0 g. of ammonium acetate and approximately 60.0 ml. of glacial acetic acid in a liter of distilled water. The pH of the solution is maintained between about 4.4 and 4.6.

In the practice of the invention according to the automated procedure, iron-free distilled water is pumped through the system for 10 minutes. The system is then switched to reagent and the pumping is continued until a steady base line is obtained on the recorder chart. The base line is set to 0.01A (95 percent transmission).

The standards in the sample tray are aspirated at a rate of 20 to 60' (2:1 wash ratio) samples per hour. The specimens to be analyzed are then sampled, with a standard glucose specimen which is aspirated intermittently to insure qualitative control. p The glucose content of each specimen is determined by reference to a calibration curve prepared by plotting the corrected absorbances of the glucose standards against concentrations in mg./ 100 ml. Table l sets forth a comparison of results obtained when 10 randomly selected plasma specimens were analyzed utilizing the automated and manual glucose procedures of the present invention.

TABLE I Comparison of Manual and Automated Glucose Analysis (mg/100 ml.)

Specimen No. Manual Automated Difference In Table II, the recovery of glucose added to pooled serum aliquots is given. An average recovery of 99.3 percent (range 94.2-l03.5 percent was realized.)

TABLE II.--RECOVERY OF GLUCOSE ADDED TO SERUM For a fuller understanding of the nature and objects of the present invention, reference may be had to the following examples which are given merely as further illustrations of the invention and are not to be construed in a limiting sense.

EXAMPLE 1 To a stirred solution off 22.0 g. of 7-bromo-l,3-dihydro-5- (2-pyridyl)-2H l,4-benzodiazepin 2-one in 55.0 ml. of dry N,N-dimethylformamide was treated with 11.0 ml. of a methanolic solution of sodium methoxide (0.0835 mole of 75 4 EXAMPLE 2 The 7-bromol ,3-dihydrol-( 3-dimethylaminopropyl )-5 2 was dissolved in sufficient methanol to provide a 10 percent solution. This solution was then saturated with hydrogen chloride. A sufficient amount of ether was added to cause turbidity. The resultant mixture was allowed to cool for several hours. 7-Bromol ,3-dihydrol 3-dimethylaminopropyl)-5-( 2 9y y 2H 1L .-.l2=nm iiaz9p n: 1e d ydr9.h. 2n'ds precipitated out on standing and was separated by filtration. The salt was recrystallized from a methanol-ether mixture as pale yellow prisms, MP. l8l-l 83 dec.

EXAMPLE 3 This example demonstrates the applicability of the test method to either blood serum or plasma.

In the method, aliquots of plasma or serum were added in 0.1 ml. quantities to 2.4 ml. of a tungstic acid solution prepared by mixing one volume 10 percent sodium tungstate and 8 volumes N/ l2 sulfuric acid. Each mixture was well mixed and then centrifuged at 2,500 rpm. for IS minutes. A 0.1 ml. aliquot of the clear supernatant liquid was treated with 2.0 ml. of a ferricyanide solution which had been prepared by dissolving 0.1 15 g. of potassium ferricyanide in one liter of a 2 percent aqueous solution of sodium carbonate. ,The deproteinized fluid ferricyanide mixture was heated for 5 minutes in a boiling water bath, rapidly cooled to about 25 C. and treated with 2.0 ml. of a ferric ion reagent prepared by dissolving 0.27 g. ferric chloride hexahydrate in one liter of an acetate buffer comprising 272.0 g. sodium acetate and 294.0

- ml. glacial acetic acid, and 2.0 ml. of a solution prepared by dissolving 2.0 g. of the compound produced in Example 2 in one liter of 1M acetate bufl'er. The solutions were thoroughly mixed and the absorbance of the violet blue color that develops was measured after about 10 minutes against a reagent blank at 580 nm in a Coleman Spectrophotometer using a cuvette with a 19 mm. light path.

The glucose content of the specimens was obtained by reference to a calibration curve prepared by plotting the absorbances (A) given by standard glucose solutions treated in the same manner against concentration or by the Beer-Lambert formula. Utilizing 4.0 mcg. glucose/0.1 ml. as a standard, the concentration of the specimen was calculated according to the formula:

(Absorbance of Specimen/Absorbance of Standard) x l00 mg. glucose/ ml.

For comparative purposes, glucose analyses were also conducted on a like number of samples utilizing a modified Folin- Wu procedure as described by B D. Tonks in American Journal of Clinical Pathology, 22:1009, (l952).

The results obtained utilizing the aforesaid two techniques 2? 595.1%?! thef ll w s il Benzediazeplne test Folin-Wu Difference Specimen (mg. glucose/ (mg. glucose] (mg. glucose] Difference,- number 100 ml.) 100 ml.) 100 ml.) percent The comparative data obtained utilizing plasma specimens was completely analogous to that with serum.

Utilizing similar reagents and quantities as were employed in Example 3, tests were conducted utilizing the compound prepared in Example 2 and comparing the results with the glucose content deproteinized plasma prepared as described in B. Klein in Clinical Chemistry, 5; 62, (1959) and designated Somogyi filtrates.

The results obtained are set forth in the following table:

In an analogous manner to that employed in Examples 3 and 4, serum specimens from 20 randomly selected blood samples obtained from healthy individuals and hospitalized patients were tested for glucose content. For comparative purposes, the glucose content of the same blood sample was also determined utilizing a standard glucose oxidase procedure. The glucose oxidase procedure employed herein is described in detail by R. Richterich and J. P. Colombo in Klin. Woch., 40, 1208, (1962) and A. Saifer and S. Gerstenfeld in J. Lab. Clin. Med., 51, 448, (1958).

The results obtained utilizing the two techniques are set forth in the following table:

Comparison of Glucose Analyses (milligrams glucose/100 ml.)

1. A process for quantitating the glucose content of blood serum or plasma comprising:

a. treating a deproteinized sample of blood serum or plasma with an aqueous alkaline solution containing a source of ferricyanide ions;

b. heating the mixture from step (a) to a temperature of from about 90C. to about l00C.;

c. adding to the mixture from step (b) a source of ferric iron ions;

d. reacting the mixture of step (c) with a benzodiazepine compound selected from the group of the compounds of the formula wherein A is selected from the group consisting of and B is selected from the group of hydrogen, lower alkyl and C uHzn rt is an integer from 2 t o 7 R3 is selected from the group consisting of hydrogen, hydroxy, lower alkylIlower allioxy a nd lower alkanoyloxy; R is Z-pyridyl; R is selected from the group consisting of lower alkyl, hydrogen,

and

GEN

gnd R and "R6, where taken together with their attached nitrogenatom, from a radical selected from the group consisting of piperazinyl, lower alkyl substituted piperazinyl, pyrrolidinyl, lower alkyl substituted pyrrolidinyl, piperidinyl, and lower alkyl substituted piperidinyl; R is lower alkyl; and R is selected from the group consisting of lower alkyl and hydrogen, and water soluble acid addition salts thereof; and

e. colorimetrically quantitating the glucose present by means of said color.

2. The process in accordance with claim 1 wherein said source of ferric ions consists essentially of an aqueous solution of ferric chloride buffered to a pH of between from about 4.0 to about 5.0.

3. The process in accordance with claim 1 wherein said benzodiazepine compound is added as an aqueous solution buffered to a pH of from about 4.0 toabout 5.0.

4. The process in accordance with claim 1 wherein said benzodiazepine compound is selected from the group consisting of 7-bromo-l ,3-dihydro-l-( 3-dimethylaminopropyl)-5-(2- pyridyl)-2H-l,4-benzodiazepin-2-one and water soluble acid addition salts thereof.

1 1 l2 5. A process for quantitating the glucose content of blood 7. The process in accordance with claim 5 wherein said j serum or plasma comprising: buffer present in the aqueous solution containing ferric a. treating a deproteinized sample of blood serum or plasma chloride and the aqueous solution containing the with an aqueous alkaline solution containing a source of benzodiazepine compound is a buffer pair comprising a water ferricyanide ions; 5 soluble salt of acetic acid and acetic acid.

b. heating the mixture from step (a) to a temperature of 8 A method for the quantitative analysis of the glucose confrom about 90C. to about 100C; tent of blood plasma or serum consisting essentially of providc. adding tov the mixture of step (b) an aqueous solution ing in continuous flow, the sequential steps comprising:

containing ferric chloride and abuffer; a. combining in continuous flow a measured specimen of d. adding to the mixture of step (c) an aqueous solution 10 plasma or serum with an isotonic solution of sodium containing a buffer and a benzodiazepine compound chloride; selected from the group consisting of compounds of the b. passing said mixture through a separating zone, thereby formula separating by dialysis in said zone from said mixture a clear aqueous solution; c. mixing said clear aqueous solution with a reagent com- N-B H prising an alkaline aqueous solution of a water soluble ferricyanide salt; R, d. passing said aqueous mixture through heating means thereby raising the temperature thereof to from about A I 95C. to about iooc.;'

e. mixing said heated aqueous mixture by concurrent flow h i A i selected from the group consisting of with a first reagent comprising a buffered aqueous solution of a ferric iron salt and a second reagent comprising a buffered, aqueous solution of a color-forming compound \m selected from the group consisting of compounds of the i l formula and R2 N-B H R; 0 B is selected from the group consisting of A/ 3 o wt, I wherein A is selected from the group consisting of and Cl-l,; R is selected from the group consisting of 1 halogen, hydrogen, trifluoromethyl, nitro, and amino; R, is selected from the group consisting of 40 and H C='N r; R1 Rs 4 \O r H B is selected from the group consisting of hydrogen, lower alkyl and 0 Rs -H o HhN and --CH,--; R, is selected from the group consisting of RB halogen, hydrogen, trifluoromethyl, nitro, and amino; R, is

selected from'the group consisting of n is an integer from 2 to 7; R; is selected from t h e group consisting of hydrogen, hydroxy, lower alkyl, lower allioxy and H lower alkanoyloxy; R, is 2-pyridyl; R is selected from the group consisting of lower alkyl; hydrogen,

fiNH2 hydrogen, lower alkyl and and s GEN CnH2nN jl ld R and R where taken together with their attached nitrogen atom, fonn a radical selected from the group consist- M ing of piperazinyl, lower alkyl substituted piperazinyl, pyrn is an integer from 2 to 7; R is selected from the gr o gn rolidinyl, lower alkyl substituted pyrrolidinyl, piperidinyl, and sisting of hydrogen, hydroxy, lower alkyl, lower alkoxy and lower alkyl substituted piperidinyl; R is lower alkyl; and R, is lower alkanoyloxy; R is 2-pyridyl; R is selected from the selected from the group consisting of lower alkyl and group consisting of lower alkyl; hydrogen, hydrogen and water soluble acid addition salts thereof; and

e. colorimetrically quantitating the glucose present by means of said color.

6. The process in accordance with claim 5 wherein said source of ferricyanide ions is potassium ferricyanide. and

GEN

; and R and R;, where taken together with their attached nitrogen atom, form a radical selected from the group consisting of piperazinyl, lower alkyl substituted piperazinyl, pyrrolidinyl, lower alkyl substituted pyrrolidinyl, piperidinyl, and

lower alkyl substituted piperidinyl; R is lower alkyl; and R is selected from the group consisting of lower alkyl and hydrogen thereof and water soluble acid addition salts thereof thereby forming a colored solution; and

f. flowing said colored solution to an analyzing zone and photometrically determining quantitatively the amount of glucose present during the flow of said colored solution through said analyzing zone.

9. The method in accordance with claim 8 wherein said first reagent and said second reagent are buffered to a pH of from about 4.0 to about 5.0 with a buffer pair comprising a water soluble salt of acetic acid and acetic acid.

10. The method in accordance with claim 8 wherein said colorforming compound is selected from the group consisting of 7-bromo-l ,3-dihydrol 3-dimethylaminopropyl)-5-( 2- pyridyl)-2H-1,4-benzodiazepin-2-one and water soluble acid addition salts thereof.

11. The method in accordance with claim 8 wherein said water soluble ferricyanide salt is potassium ferricyanide and said ferric iron salt is ferric chloride.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3098717 *Apr 27, 1959Jul 23, 1963Technicon InstrFluid treatment method and apparatus with double-flow colorimeter
US3449081 *Mar 29, 1965Jun 10, 1969Electronic Instr CoTest kit
US3506404 *Dec 19, 1967Apr 14, 1970Hoffmann La RocheColorimetric method for determining iron in blood
Non-Patent Citations
Reference
1 *Aloe Scientific Co., Catalog 103, p. 1011, 1041, 1065, 1073
2 *Hawk et al., Practical Physiological Chemistry, 13th ed., McGraw Hill Co., QP514H4, 1954, p. 567, 575
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3920969 *Jan 31, 1974Nov 18, 1975Berglas Robert EDigital glucose analyzer
US4095948 *Jul 22, 1976Jun 20, 1978Hoffmann-La Roche Inc.Abenzidine or diphenyline and peroxidase as color indicator
US4319883 *Mar 26, 1980Mar 16, 1982Atto CorporationMethod for determining catecholic compounds and their related compounds
US4645742 *Jul 18, 1984Feb 24, 1987Baker John RColorimetric analysis with nitro-blue tetra zolium; detecting diabetes
US4953552 *Apr 21, 1989Sep 4, 1990Demarzo Arthur PBlood glucose monitoring system
US5571723 *May 3, 1993Nov 5, 1996Evans; Cody A.Method of testing for diabetes that reduces the effect of interfering substances
US6103033 *Mar 4, 1998Aug 15, 2000Therasense, Inc.Process for producing an electrochemical biosensor
US6120676 *Jun 4, 1999Sep 19, 2000Therasense, Inc.Method of using a small volume in vitro analyte sensor
US6134461 *Mar 4, 1998Oct 17, 2000E. Heller & CompanyElectrochemical analyte
US6143164 *Dec 16, 1998Nov 7, 2000E. Heller & CompanySmall volume in vitro analyte sensor
US6162611 *Jan 3, 2000Dec 19, 2000E. Heller & CompanyDetecting preferential monosaccharide levels in human using electrochemical detector; grafting detector into human, generating calibration value and monitoring detector signals
US6175752Apr 30, 1998Jan 16, 2001Therasense, Inc.Analyte monitoring device and methods of use
US6251260Aug 24, 1998Jun 26, 2001Therasense, Inc.Potentiometric sensors for analytic determination
US6284478Dec 4, 1996Sep 4, 2001E. Heller & CompanyElectrochemical sensor; for in situ monitoring of glucose in diabetics
US6299757Oct 6, 1999Oct 9, 2001Therasense, Inc.Analytical sensors for the detection of bioanalytes; especially monitoring glucose levels in diabetic patients
US6329161Sep 22, 2000Dec 11, 2001Therasense, Inc.A flexible analyte sensor that is adapted for external positioning to an animal and for connection to a device for measuring an electrical signal generated by the sensor; for measuring glucose concentration in diabetes
US6338790Apr 21, 1999Jan 15, 2002Therasense, Inc.Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6461496Oct 27, 1999Oct 8, 2002Therasense, Inc.Blood glucose
US6484046Jul 10, 2000Nov 19, 2002Therasense, Inc.Electrochemical analyte sensor
US6514718Nov 29, 2001Feb 4, 2003Therasense, Inc.Subcutaneous glucose electrode
US6551494Apr 6, 2000Apr 22, 2003Therasense, Inc.Small volume in vitro analyte sensor
US6565509Sep 21, 2000May 20, 2003Therasense, Inc.Analyte monitoring device and methods of use
US6576101Oct 6, 1999Jun 10, 2003Therasense, Inc.Small volume in vitro analyte sensor
US6591125Jun 27, 2000Jul 8, 2003Therasense, Inc.Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6592745May 17, 2000Jul 15, 2003Therasense, Inc.Method of using a small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6616819Nov 4, 1999Sep 9, 2003Therasense, Inc.Small volume in vitro analyte sensor and methods
US6618934Jun 15, 2000Sep 16, 2003Therasense, Inc.Method of manufacturing small volume in vitro analyte sensor
US6654625Jun 16, 2000Nov 25, 2003Therasense, Inc.Mass transport limited in vivo analyte sensor
US6749740Dec 28, 2001Jun 15, 2004Therasense, Inc.Small volume in vitro analyte sensor and methods
US6881551Jan 28, 2003Apr 19, 2005Therasense, Inc.Insulated, non-corroding conducting metal or carbon wire-based small subcutaneous glucose sensor, allowing one-point calibration in vivo
US6942518Dec 28, 2001Sep 13, 2005Therasense, Inc.Small volume in vitro analyte sensor and methods
US6973706Mar 31, 2003Dec 13, 2005Therasense, Inc.Comprises forming channels in surfaces of the substrate, and disposing conductive material by non-impact printing to form electrode/sensor; biocompatability
US6975893Nov 25, 2003Dec 13, 2005Therasense, Inc.Mass transport limited in vivo analyte sensor
US7003340Nov 11, 2002Feb 21, 2006Abbott Diabetes Care Inc.Electrochemical analyte sensor
US7058437Apr 17, 2003Jun 6, 2006Therasense, Inc.Methods of determining concentration of glucose
US7225535Sep 12, 2003Jun 5, 2007Abbott Diabetes Care, Inc.Method of manufacturing electrochemical sensors
US7381184Nov 5, 2003Jun 3, 2008Abbott Diabetes Care Inc.Sensor inserter assembly
US7462264Jul 15, 2005Dec 9, 2008Abbott Diabetes Care Inc.Small diameter flexible electrode for in vivo amperometric monitoring of glucose or lactate with sensing layer of glucose-specific or lactate-specific enzyme (glucose oxidase or lactate oxidase) crosslinked with polyvinylimidazole, polyvinylpyridine, or acrylamide-vinylimidazole copolymer
US7550069Sep 12, 2003Jun 23, 2009Abbott Diabetes Care Inc.Non-leachable or diffusible redox mediator; for glucose or lactate concentrations; to monitor glucose in diabetic patients and lactate during critical care events
US7563350Sep 15, 2003Jul 21, 2009Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US7582059Sep 6, 2007Sep 1, 2009Abbott Diabetes Care Inc.Sensor inserter methods of use
US7620438Mar 31, 2006Nov 17, 2009Abbott Diabetes Care Inc.Method and system for powering an electronic device
US7721412Aug 16, 2005May 25, 2010Abbott Diabetes Care Inc.Method of making an electrochemical sensor
US7766829Nov 4, 2005Aug 3, 2010Abbott Diabetes Care Inc.Method and system for providing basal profile modification in analyte monitoring and management systems
US7811231Dec 26, 2003Oct 12, 2010Abbott Diabetes Care Inc.Continuous glucose monitoring system and methods of use
US7860544Mar 7, 2007Dec 28, 2010Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US7861397Oct 30, 2007Jan 4, 2011Abbott Diabetes Care Inc.Method of making an electrochemical sensor
US7869853Aug 6, 2010Jan 11, 2011Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US7879213Oct 30, 2007Feb 1, 2011Abbott Diabetes Care Inc.Sensor for in vitro determination of glucose
US7885699Aug 6, 2010Feb 8, 2011Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US7906009Jul 30, 2008Mar 15, 2011Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US7909984Feb 7, 2008Mar 22, 2011Abbott Diabetes Care Inc.system for determining the concentration of analyte in a biological fluid from a patient, comprising:at least one substrate associated with at least one transducer;a piercing member adapted to pierce a site on the patient to cause blood to flow therefrom;a sensor positioned adjacent to the site
US7920907Jun 7, 2007Apr 5, 2011Abbott Diabetes Care Inc.Analyte monitoring system and method
US7928850May 8, 2008Apr 19, 2011Abbott Diabetes Care Inc.Analyte monitoring system and methods
US7976778Jun 22, 2005Jul 12, 2011Abbott Diabetes Care Inc.Blood glucose tracking apparatus
US7988845Jan 28, 2008Aug 2, 2011Abbott Diabetes Care Inc.Integrated lancing and measurement device and analyte measuring methods
US7996054Feb 20, 2006Aug 9, 2011Abbott Diabetes Care Inc.Electrochemical analyte sensor
US8029442Sep 6, 2007Oct 4, 2011Abbott Diabetes Care Inc.Sensor inserter assembly
US8066639Jun 4, 2004Nov 29, 2011Abbott Diabetes Care Inc.Glucose measuring device for use in personal area network
US8066858Oct 31, 2007Nov 29, 2011Abbott Diabetes Care Inc.Analyte sensor with insertion monitor, and methods
US8083924Sep 29, 2009Dec 27, 2011Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8083928Sep 29, 2009Dec 27, 2011Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8083929Sep 29, 2009Dec 27, 2011Abbott Diabetes Care Inc.Small volume in vitro sensor and methods of making
US8087162Sep 29, 2009Jan 3, 2012Abbott Diabetes Care Inc.Methods of making small volume in vitro analyte sensors
US8091220Oct 31, 2007Jan 10, 2012Abbott Diabetes Care Inc.Methods of making small volume in vitro analyte sensors
US8103456Jan 29, 2009Jan 24, 2012Abbott Diabetes Care Inc.Method and device for early signal attenuation detection using blood glucose measurements
US8105476Jul 30, 2007Jan 31, 2012Abbott Diabetes Care Inc.Integrated lancing and measurement device
US8112240Apr 29, 2005Feb 7, 2012Abbott Diabetes Care Inc.Method and apparatus for providing leak detection in data monitoring and management systems
US8114270Feb 7, 2008Feb 14, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8114271Sep 29, 2009Feb 14, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8117734Oct 30, 2007Feb 21, 2012Abbott Diabetes Care Inc.Method of making an electrochemical sensor
US8118992Sep 29, 2009Feb 21, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8118993Sep 29, 2009Feb 21, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8123686Mar 1, 2007Feb 28, 2012Abbott Diabetes Care Inc.Method and apparatus for providing rolling data in communication systems
US8123929Sep 29, 2009Feb 28, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8136220Oct 30, 2007Mar 20, 2012Abbott Diabetes Care Inc.Method of making an electrochemical sensor
US8142642Jul 30, 2008Mar 27, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8142643Sep 29, 2009Mar 27, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8149117Aug 29, 2009Apr 3, 2012Abbott Diabetes Care Inc.Analyte monitoring system and methods
US8153063Sep 29, 2009Apr 10, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8162829Mar 30, 2009Apr 24, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8163164Sep 29, 2009Apr 24, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8168051Oct 30, 2007May 1, 2012Abbott Diabetes Care Inc.Sensor for determination of glucose
US8175673Nov 9, 2009May 8, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8177716Dec 21, 2009May 15, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8182670Sep 29, 2009May 22, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8182671Sep 29, 2009May 22, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8186044Apr 13, 2007May 29, 2012Abbott Diabetes Care Inc.Method of manufacturing small volume in vitro analyte sensors
US8187183Oct 11, 2010May 29, 2012Abbott Diabetes Care Inc.Continuous glucose monitoring system and methods of use
US8187895Sep 29, 2009May 29, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8192611Sep 29, 2009Jun 5, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8211363Sep 29, 2009Jul 3, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8221685Sep 29, 2009Jul 17, 2012Abbott Diabetes Care Inc.Small volume in vitro sensor and methods of making
US8224413Oct 10, 2008Jul 17, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8226555Mar 18, 2009Jul 24, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8226557Dec 28, 2009Jul 24, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8226558Sep 27, 2010Jul 24, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8226815Sep 29, 2009Jul 24, 2012Abbott Diabetes Care Inc.Small volume in vitro sensor and methods of making
US8226891Mar 31, 2006Jul 24, 2012Abbott Diabetes Care Inc.Analyte monitoring devices and methods therefor
US8231532Apr 30, 2007Jul 31, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8235896Dec 21, 2009Aug 7, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8236242Feb 12, 2010Aug 7, 2012Abbott Diabetes Care Inc.Blood glucose tracking apparatus and methods
US8255031Mar 17, 2009Aug 28, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8260392Jun 9, 2008Sep 4, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8262996Sep 29, 2009Sep 11, 2012Abbott Diabetes Care Inc.Small volume in vitro sensor and methods of making
US8265726Nov 9, 2009Sep 11, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8268144Sep 29, 2009Sep 18, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8268163Sep 29, 2009Sep 18, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8268243Dec 28, 2009Sep 18, 2012Abbott Diabetes Care Inc.Blood glucose tracking apparatus and methods
US8272125Sep 29, 2009Sep 25, 2012Abbott Diabetes Care Inc.Method of manufacturing in vitro analyte sensors
US8273022Feb 13, 2009Sep 25, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8273227Oct 30, 2007Sep 25, 2012Abbott Diabetes Care Inc.Sensor for in vitro determination of glucose
US8273241Sep 29, 2009Sep 25, 2012Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8275439Nov 9, 2009Sep 25, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8287454Sep 27, 2010Oct 16, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8306598Nov 9, 2009Nov 6, 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8333714Sep 10, 2006Dec 18, 2012Abbott Diabetes Care Inc.Method and system for providing an integrated analyte sensor insertion device and data processing unit
US8346336Mar 18, 2009Jan 1, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8346337Jun 30, 2009Jan 1, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8353829Dec 21, 2009Jan 15, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8357091Dec 21, 2009Jan 22, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8362904Apr 18, 2011Jan 29, 2013Abbott Diabetes Care Inc.Analyte monitoring system and methods
US8366614Mar 30, 2009Feb 5, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8372005Dec 21, 2009Feb 12, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8372261Sep 29, 2009Feb 12, 2013Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8377378Sep 29, 2009Feb 19, 2013Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8380273Apr 11, 2009Feb 19, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8391945Mar 17, 2009Mar 5, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8409131Mar 7, 2007Apr 2, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8414749Nov 12, 2008Apr 9, 2013Abbott Diabetes Care Inc.Subcutaneous glucose electrode
US8414750Sep 29, 2010Apr 9, 2013Abbott Diabetes Care Inc.Subcutaneous glucose electrode
US8425743Mar 12, 2010Apr 23, 2013Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8425758Sep 29, 2009Apr 23, 2013Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8449758Sep 29, 2009May 28, 2013Abbott Diabetes Care Inc.Small volume in vitro analyte sensor and methods of making
US8456301May 8, 2008Jun 4, 2013Abbott Diabetes Care Inc.Analyte monitoring system and methods
US8461985May 8, 2008Jun 11, 2013Abbott Diabetes Care Inc.Analyte monitoring system and methods
US8463351Aug 6, 2010Jun 11, 2013Abbott Diabetes Care Inc.Electrochemical analyte sensor
US8465425Jun 30, 2009Jun 18, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8473021Jul 31, 2009Jun 25, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8473220Jan 23, 2012Jun 25, 2013Abbott Diabetes Care Inc.Method and device for early signal attenuation detection using blood glucose measurements
US8480580Apr 19, 2007Jul 9, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8512239Apr 20, 2009Aug 20, 2013Abbott Diabetes Care Inc.Glucose measuring device for use in personal area network
US8512243Sep 30, 2005Aug 20, 2013Abbott Diabetes Care Inc.Integrated introducer and transmitter assembly and methods of use
US8532731May 8, 2009Sep 10, 2013Abbott Diabetes Care Inc.Methods of determining analyte concentration
US8545403Dec 28, 2006Oct 1, 2013Abbott Diabetes Care Inc.Medical device insertion
US8571624Dec 29, 2004Oct 29, 2013Abbott Diabetes Care Inc.Method and apparatus for mounting a data transmission device in a communication system
US8585591Jul 10, 2010Nov 19, 2013Abbott Diabetes Care Inc.Method and system for providing basal profile modification in analyte monitoring and management systems
US8588881Mar 2, 2007Nov 19, 2013Abbott Diabetes Care Inc.Subcutaneous glucose electrode
US8593109Nov 3, 2009Nov 26, 2013Abbott Diabetes Care Inc.Method and system for powering an electronic device
US8593287Jul 20, 2012Nov 26, 2013Abbott Diabetes Care Inc.Analyte monitoring system and methods
US8597189Mar 3, 2009Dec 3, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8597575Jul 23, 2012Dec 3, 2013Abbott Diabetes Care Inc.Analyte monitoring devices and methods therefor
US8602991Jun 7, 2010Dec 10, 2013Abbott Diabetes Care Inc.Analyte sensor introducer and methods of use
US8612159Feb 16, 2004Dec 17, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8613703May 29, 2008Dec 24, 2013Abbott Diabetes Care Inc.Insertion devices and methods
US8617071Jun 21, 2007Dec 31, 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8622903May 25, 2012Jan 7, 2014Abbott Diabetes Care Inc.Continuous glucose monitoring system and methods of use
US8622906Dec 21, 2009Jan 7, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8641619Dec 21, 2009Feb 4, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8647269Apr 20, 2009Feb 11, 2014Abbott Diabetes Care Inc.Glucose measuring device for use in personal area network
US8649841Apr 3, 2007Feb 11, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8650751Sep 29, 2009Feb 18, 2014Abbott Diabetes Care Inc.Methods of making small volume in vitro analyte sensors
US8652043Jul 20, 2012Feb 18, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8660627Mar 17, 2009Feb 25, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8665091Jun 30, 2009Mar 4, 2014Abbott Diabetes Care Inc.Method and device for determining elapsed sensor life
US8666469Nov 16, 2007Mar 4, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8668645Jan 3, 2003Mar 11, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8670815Apr 30, 2007Mar 11, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8672844Feb 27, 2004Mar 18, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8676513Jun 21, 2013Mar 18, 2014Abbott Diabetes Care Inc.Method and device for early signal attenuation detection using blood glucose measurements
US8688188Jun 30, 2009Apr 1, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8701282Sep 29, 2009Apr 22, 2014Abbott Diabetes Care Inc.Method for manufacturing a biosensor
US8706180Jun 10, 2013Apr 22, 2014Abbott Diabetes Care Inc.Electrochemical analyte sensor
US8728297Apr 13, 2006May 20, 2014Abbott Diabetes Care Inc.Small volume in vitro analyte sensor
US8732188Feb 15, 2008May 20, 2014Abbott Diabetes Care Inc.Method and system for providing contextual based medication dosage determination
US8734346Apr 30, 2007May 27, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8734348Mar 17, 2009May 27, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8738109Mar 3, 2009May 27, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8741590Apr 3, 2007Jun 3, 2014Abbott Diabetes Care Inc.Subcutaneous glucose electrode
US8744545Mar 3, 2009Jun 3, 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US8764657Mar 30, 2012Jul 1, 2014Abbott Diabetes Care Inc.Medical device inserters and processes of inserting and using medical devices
US8765059Oct 27, 2010Jul 1, 2014Abbott Diabetes Care Inc.Blood glucose tracking apparatus
US20100185066 *Jan 24, 2010Jul 22, 2010Eyesense AgApparatus for measuring blood glucose concentrations
DE2658101A1 *Dec 22, 1976Jul 14, 1977Gambro AgVerfahren zur messung der konzentration von niedrigmolekularen verbindungen in komplexen medien, vorzugsweise bei medizinischen behandlungen, und vorrichtung zur durchfuehrung des verfahrens
Classifications
U.S. Classification436/95, 436/53
International ClassificationG01N33/66
Cooperative ClassificationG01N33/66
European ClassificationG01N33/66